Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation), in an 8-K filing dated June 2, 2009, announced a strategic acquisition. The company has acquired Innomar Strategies Inc., a Canadian specialty pharmaceutical services company, for approximately $13.8 million USD in cash, subject to customary working capital adjustments. This acquisition represents a move by Cencora to expand its specialty pharmaceutical services capabilities, particularly within the Canadian market.
Key Highlights
- 1Acquisition of Innomar Strategies Inc., a Canadian specialty pharmaceutical services company.
- 2Transaction value of approximately $13.8 million USD (15 million CDN) in cash.
- 3Acquisition is subject to a working capital adjustment.
- 4The acquisition aims to enhance Cencora's specialty pharmaceutical services offerings.
- 5The deal signifies international expansion for Cencora's specialty services.
- 6Filing date of the 8-K report is June 2, 2009.
Frequently Asked Questions
The primary purpose of this 8-K filing was to announce Cencora's acquisition of Innomar Strategies Inc., a Canadian specialty pharmaceutical services company.
Cencora acquired Innomar Strategies Inc. for approximately $13.8 million USD (which was 15 million CDN) in cash, with the final price subject to a working capital adjustment.
The acquisition is strategically important as it expands Cencora's presence and capabilities in the specialty pharmaceutical services sector, particularly in the Canadian market, aligning with the company's growth strategy in specialized services.
Based on the provided filing, the acquisition was for a fixed cash amount, subject only to a working capital adjustment. There is no mention of performance-based components in this announcement.